|
NJIN Monthly Newsletter
July 2025
| | |
In this edition of the NJIN monthly newsletter, we present several
vaccine-related articles and updates related to topics such as Flu, and COVID-19, and Measles.
|
| |
Vaccines, Voices, and Validity:
Confronting Misinformation and Supporting the Autism Community with Compassion and Clarity
August 12, 2025
12:00pm-1:00pm ET
Join us for an important webinar focused on addressing misinformation surrounding vaccines and autism and supporting the Autism community in clinical settings. Featuring Dr. Peter Hotez and Danielle Hall (Autism Society of America), this session will explore the rise of antivaccine activism, clarify misconceptions around autism and vaccines, and offer practical strategies to build trust and improve care for Autistic patients.
Registration is required.
Click to Register
Click the flyer to open as a high resolution PDF.
| |
Spotlight:
Vaccine Developments
| | |
Recent months have seen several significant developments in vaccination research and public health initiatives.
COVID-19
Influenza
-
The Influenza Vaccines Research and Development (R&D) Roadmap (IVR), created by the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota and published in 2021 to serve as a strategic planning tool to advance influenza vaccine R&D, has achieved significant progress. Of the 35 milestones designated "high-priority," 5 (14%) have been accomplished in whole or in part, with another 29 (83%) in progress.
RSV
-
The CDC now recommends a single dose of any FDA-licensed RSV vaccine for all adults ages 75 and older and adults ages 50–74 at increased risk of severe RSV. For more on the CDC's RSV vaccine guidance, click here.
-
FDA approved Moderna’s RSV vaccine, mRESVIA, to include adults 18 to 59 years of age who are at increased risk of severe RSV disease. Click here to learn more.
| | Featured Articles and Resources | | |
June ACIP Meeting Summary
CDC
| The newly appointed members of the Advisory Committee on Immunization Practices (ACIP) met on June 25-26 to vote on the following: |
-
One dose of clesrovimab, a monoclonal antibody for infants whose mothers are not protected by maternal respiratory syncytial virus (RSV) vaccination. Approved 5-2
-
Updated Vaccines for Children Program resolution for prevention of RSV. Approved 7-0
-
Recommendation for routine annual influenza vaccination of all persons aged over six months who do not have contraindications. Approved 6-0
-
Recommendation for children 18 years and younger to receive seasonal influenza vaccines only in single-dose formulations that are free of thimerosal as a preservative. Approved 5-1
-
Recommendation that pregnant women receive seasonal influenza vaccines only in single-dose formulations that are free of thimerosal as a preservative. Approved 5-1
-
Recommendation that all adults receive seasonal influenza vaccines only in single-dose formulations that are free of thimerosal as a preservative. Approved 5-1
The next meeting of the ACIP is scheduled for October 22-23, 2025.
|
AAP Will Continue to Publish its Own Vaccine Recommendations
AAP
| |
The CDC will be conducting a review of the child and adolescent vaccine schedules, "a move the AAP criticized as aiming to sow distrust in immunizations."
"The AAP said it will continue to publish its own evidence-based recommendations and schedules. The AAP has provided vaccine recommendations for its entire 95-year history."
The evidence-based Child and Adolescent Immunization Schedule endorsed by the American Academy of Pediatrics in November 2024 can be found here.
The Child and Adolescent Immunization Schedule, published by the CDC, which is not currently endorsed by the AAP, can be found here.
|
CDC Relaxes Rules on Stocking Vaccines in VFC Program
AAP News
| |
"Federal health officials are relaxing some of the rules for stocking vaccines in the Vaccines for Children (VFC) program."
"VFC providers no longer will have to maintain a full stock of all recommended vaccines for privately insured children if they don’t plan to offer all vaccines to this population, according to a summary of changes the Centers for Disease Control and Prevention (CDC) provided to state immunization managers and the AAP. In addition, they will not have to stock COVID-19 vaccines for VFC-eligible patients."
|
AAP Suing HHS Over Vaccine Policy 'Because We Believe Children Deserve Better'
AAP News
| "The AAP and other leading medical groups are suing Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. for making unilateral, unscientific changes to federal vaccine policy they say are an 'assault on science, public health and evidence-based medicine.'” |
CDC Confirms Worst Year for Measles since 1992
AAP News
| |
According to CDC data, 1,309 confirmed measles cases have been reported in the United States in 2025, the highest total since 1992 when 2,126 cases were reported.
92% of reported cases are among unvaccinated individuals or those whose vaccination status is unknown.
2025 has seen 29 outbreaks (3 or more related cases), accounting for 88% of confirmed cases (1,151 of 1,309). For comparison, 16 outbreaks were reported during 2024 and 69% of cases (198 of 285) were outbreak-associated.
|
FDA Requires Updated Warning About Rare Heart Risk with COVID Shots
Associated Press (AP)
| |
The Food and Drug Administration (FDA) "has expanded existing warnings on the two leading COVID-19 vaccines" to include myocarditis, a type of heart inflammation that is usually mild, mainly seen in young men.
"The new warning lists the risk of myocarditis as 8 cases per 1 million people who got the 2023-2024 COVID shots between the ages of 6 months and 64 years old."
"The FDA’s labeling change appears to conflict with some prior findings of scientists elsewhere in the U.S. government."
"The Centers for Disease Control and Prevention previously concluded there was no increased risk of myocarditis detected in government vaccine injury databases for COVID-19 shots dating back to 2022. Officials also noted that cases tend to resolve quickly and are less severe than those associated with COVID-19 infection itself, which can also cause myocarditis."
|
National Health Center Week 2025
National Association of Community Health Centers
| This year's annual National Health Center Week (NHCW) 2025 will be held August 3-9. Use the link below to find an event in your area to celebrate the vital work of health centers across the nation. | |
COVID-19
Current Epidemic Growth Status for States
CDC
| | |
Key Points
- "As of July 8, 2025, we estimate that COVID-19 infections are growing or likely growing in 25 states, declining or likely declining in 0 states, and not changing in 21 states."
-
New Jersey: Probability the COVID-19 epidemic trend is growing: 65.42% (not changing).
% of ED visits (COVID-19): 0.37% (very low)
-
Nationwide: Probability the COVID-19 epidemic trend is growing: 99.82% (growing).
% of ED visits (COVID-19): 0.44% (very low)
| | NJIN is now on Bluesky. Our goal is to continue to expand our digital presence in pursuit of our organization's mission to spread the word about vaccine safety and benefits to all individuals through timely, age-appropriate immunization against vaccine-preventable diseases. | | |
NJIN is proud to have hosted the first Community Baby Shower with the Lenni-Lenape community of Cumberland County on July 11. The Nanticoke Lenni-Lenape Tribal Nation is a recognized tribe in Cumberland County, maintaining its cultural heritage and tribal identity. Thirteen community partners worked with NJIN including personnel from NJDOH’s Biomonitoring and Exposure Assessment Program who conducted lead and mercury exposure testing for pregnant women and children in attendance. The event was a tremendous success!
For a full list of our upcoming community events, click here.
| | |
July 23, 2025 (Wed)
NJIN Education and Events Committee
1:00pm - 2:00pm
August 14, 2025 (Thu)
NJIN Steering Committee
9:00am - 10:00am
| | We Want to Hear From You! | | |
The NJIN team encourages input from our readers. Any suggestions on topics, resources, or other ideas that you'd like to see included going forward are welcome!
Please share your feedback with us at NJIN@njaap.org.
| | | | |
